BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Myelofibrosis and MPNs clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for myelofibrosis: 61 (35 sponsors; 6 newly posted in the last 180 days, 5 stopped in the last 180 days; 1 new-entrant sponsors). Momentum score 10.7, rank 63 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 24, Phase 2 18, Phase 3 13, Phase 4 1, N/A 5.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Novartis Pharmaceuticals NVS | 4 | P3 2, P4 1, P1 1 | 0 | 0 |
| Celgene | 2 | P3 2 | 0 | 0 |
| Chengdu Zenitar Biomedical Technology Co., Ltd | 4 | P3 1, P2 3 | 1 | 0 |
| AbbVie ABBV | 3 | P1 2, P3 1 | 0 | 2 |
| Karyopharm Therapeutics Inc KPTIQ | 3 | P3 1, P2 2 | 0 | 0 |
| Geron Corporation GERN | 2 | P1 1, P3 1 | 0 | 1 |
| Swedish Orphan Biovitrum | 2 | P3 1, NA 1 | 1 | 1 |
| Takeda TAK | 2 | P2 1, P3 1 | 1 | 0 |
| Kartos Therapeutics, Inc. | 1 | P3 1 | 0 | 1 |
| Merck Sharp & Dohme LLC MRK | 1 | P3 1 | 0 | 0 |
| PharmaEssentia | 1 | P3 1 | 0 | 0 |
| Incyte Corporation INCY | 6 | P1 6 | 0 | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 5 | P1 3, P2 2 | 2 | 3 |
| Bristol-Myers Squibb BMY | 2 | P2 1, NA 1 | 0 | 0 |
| GlaxoSmithKline | 2 | P2 2 | 0 | 2 |
| iOnctura | 2 | P1 1, P2 1 | 0 | 0 |
| Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 1 | P1 1 | 0 | 0 |
| Aspera Biomedicines, Inc. | 1 | P1 1 | 0 | 0 |
| Cellenkos, Inc. | 1 | P1 1 | 0 | 1 |
| CERo Therapeutics Holdings, Inc. CERO | 1 | P1 1 | 0 | 1 |
| Chiesi Farmaceutici S.p.A. | 1 | NA 1 | 0 | 0 |
| Damora Therapeutics DMRA new entrant | 1 | P1 1 | 1 | 0 |
| Disc Medicine, Inc IRON | 1 | P2 1 | 0 | 1 |
| Eilean Therapeutics | 1 | P1 1 | 0 | 0 |
| Eilean Therapeutics AU Pty Ltd | 1 | P1 1 | 0 | 0 |
New-entrant sponsors: Damora Therapeutics.
Recently stopped trials
- NCT06397313 Ryvu Therapeutics SA - terminated: Sponsor decision RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
- NCT05115344 Guizhou Bailing Group Pharmaceutical Co Ltd - withdrawn: Withdrawn due to duplicate registration Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors
- NCT01437787 Bristol-Myers Squibb - terminated: Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
- NCT01523171 Bristol-Myers Squibb - terminated: Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
- NCT04640025 Incyte Corporation - terminated: The decision to close the study was made due to the expiration of remaining drug supply. A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Italfarmaco | NCT01761968 Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | Chronic Myeloproliferative Neoplasms | active not recruiting | 90 |
| 2026-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06122831 A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) | Myelofibrosis | recruiting | 92 |
| 2026-12-11 est. | P2 | GlaxoSmithKline | NCT03441113 Extended Access of Momelotinib in Adults With Myelofibrosis | Primary Myelofibrosis | active not recruiting | 237 |
| 2026-12-31 est. | P3 | Kartos Therapeutics, Inc. | NCT06479135 Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis; MF | recruiting | 600 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-05 est. | P3 | Swedish Orphan Biovitrum | NCT03165734 A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofib | active not recruiting | 407 |
| 2026-09 est. | P1/P2 | Silence Therapeutics plc SLN | NCT05499013 Study to Assess SLN124 in Patients With Polycythemia Vera | Polycythemia Vera | active not recruiting | 69 |
| 2026-09 est. | P2 | Karyopharm Therapeutics Inc KPTIQ | NCT04562870 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | Myelofibrosis | active not recruiting | 112 |
| 2026-07 est. | P3 | Italfarmaco | NCT06093672 Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | Polycythemia Vera | recruiting | 220 |
| 2026-06-30 | P2 | Ryvu Therapeutics SA | NCT06397313 RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis | Myelofibrosis | terminated | 36 |
| 2026-06-30 est. | P3 | PharmaEssentia Japan K.K. | NCT04655092 Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | Polycythemia Vera (PV) | recruiting | 67 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "myelofibrosis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.